Natural killer cell monitoring in cutaneous melanoma - new dynamic biomarker

Isvoranu,Gheorghița; Surcel,Mihaela; Huică,Radu-Ionuț; Munteanu,Adriana Narcisa; Pîrvu,Ioana Ruxandra; Ciotaru,Dan; Constantin,Carolina; Bratu,Ovidiu; Neagu,Monica; Ursaciuc,Cornel

doi:10.3892/ol.2019.10069

Natural killer cell monitoring in cutaneous melanoma - new dynamic biomarker

Authors:
- Gheorghița Isvoranu
- Mihaela Surcel
- Radu-Ionuț Huică
- Adriana Narcisa Munteanu
- Ioana Ruxandra Pîrvu
- Dan Ciotaru
- Carolina Constantin
- Ovidiu Bratu
- Monica Neagu
- Cornel Ursaciuc
View Affiliations

Affiliations: Animal Husbandry, ‘Victor Babeș’ National Institute of Pathology, 050096 Bucharest, Romania, Immunobiology Laboratory, ‘Victor Babeș’ National Institute of Pathology, 050096 Bucharest, Romania, Clinical Department 3, Central Military Hospital, 010825 Bucharest, Romania
Published online on: February 25, 2019 https://doi.org/10.3892/ol.2019.10069
Pages: 4197-4206
Copyright: © Isvoranu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is responsible for most skin cancer deaths in humans. The immune system plays a major role in regulating tumor cell proliferation by initiating defence responses against tumor aggression. Research on murine cancer models allow for a better understanding of immune response in malignancies, revealing specific changes of the immune status in the presence of tumors. Melanoma resistance to conventional therapies and its high immunogenicity justify the development of new therapies. These features reinforce melanoma as a suitable model for studying antitumor immunity. Recent findings on NK cell activation in cancer patients indicate that several important parameters, such as tumor capacity to modulate the function and phenotype of NK cells, require consideration for the choice of an NK-based therapy. In this study, we investigated T-CD4+ and T-CD8+ lymphocytes, B lymphocytes and NK cells in peripheral blood and spleen cells suspension from melanoma-bearing mice compared to healthy controls in order to assess the potential for tumor growth-promoting immunosuppression. Our results indicate that in a melanoma-bearing mouse model the percentage of NK cells in spleen is reduced and that their phenotype is different compared to control mouse NK cells.

View Figures

View References

1	Chin L, Garraway LA and Fisher DE: Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev. 20:2149–2182. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lakshmikanth T and Johansson MH: Current perspectives on immunomodulation of NK cells in melanoma. Melanoma in the Clinic - Diagnosis. Management and Complications of Malignancy; Mandi M: InTech, Rijeka: pp. 133–162. 2011
3	Serban ED, Farnetani F, Pellacani G and Constantin MM: Role of in vivo reflectance confocal microscopy in the analysis of melanocytic lesions. Acta Dermatovenerol Croat. 26:64–67. 2018.PubMed/NCBI
4	Rangwala S and Tsai KY: Roles of the immune system in skin cancer. Br J Dermatol. 165:953–965. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lupu M, Caruntu A, Caruntu C, Papagheorghe LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki M, et al: Neuroendocrine factors: The missing link in non-melanoma skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
6	Caruntu C, Boda D, Constantin C, Caruntu A and Neagu M: Catecholamines increase in vitro proliferation of murine B16F10 melanoma cells. Acta Endocrinol (Copenh). 10:545–558. 2014.
7	Neagu M: The immune system - a hidden treasure for biomarker discovery in cutaneous melanoma. Adv Clin Chem. 58:89–140. 2012. View Article : Google Scholar : PubMed/NCBI
8	Holtan SG, Creedon DJ, Thompson MA, Nevala WK and Markovic SN: Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol. 2011:3163142011. View Article : Google Scholar : PubMed/NCBI
9	Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI
10	Dons'koi BV, Chernyshov VP and Osypchuk DV: Measurement of NK activity in whole blood by the CD69 upregulation after co-incubation with K562, comparison with NK cytotoxicity assays and CD107a degranulation assay. J Immunol Methods. 372:187–195. 2011. View Article : Google Scholar : PubMed/NCBI
11	Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M and Caligiuri MA: CD56^bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity. Blood. 101:3052–3057. 2003. View Article : Google Scholar : PubMed/NCBI
12	Colucci F, Caligiuri MA and Di Santo JP: What does it take to make a natural killer? Nat Rev Immunol. 3:413–425. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ursaciuc C, Surcel M, Huică R, Ciotaru D, Dobre M, Pîrvu IR, Cirimbei C, Mischianu D, Bratu O, Isvoranu G, et al: CD56^dim/CD56^bright NK cell subpopulations and CD16/CD57 expression correlated with tumor development stages. S East Eur J Immunol. 2016:1–5. 2016. View Article : Google Scholar
14	Hayakawa Y and Smyth MJ: CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 176:1517–1524. 2006. View Article : Google Scholar : PubMed/NCBI
15	Inngjerdingen M, Kveberg L, Naper C and Vaage JT: Natural killer cell subsets in man and rodents. Tissue Antigens. 78:81–88. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sun JC and Lanier LL: NK cell development, homeostasis and function: Parallels with CD8⁺ T cells. Nat Rev Immunol. 11:645–657. 2011. View Article : Google Scholar : PubMed/NCBI
17	Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E and Walzer T: Maturation of mouse NK cells is a 4-stage developmental program. Blood. 113:5488–5496. 2009. View Article : Google Scholar : PubMed/NCBI
18	National Research Council: Animal care and use program. In: Guide for the Care and Use of Laboratory Animals. 8th. National Academy Press; Washington, DC: pp. 11–35. 2011
19	Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, Teixeira-Guedes C, Soares-Maia R, da Costa RG, Colaço B, Pires MJ, Colaço J, Ferreira R and Ginja M: Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Animal. 42:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
20	Freud AG, Zhao S, Wei S, Gitana GM, Molina-Kirsch HF, Atwater SK and Natkunam Y: Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia. Am J Clin Pathol. 140:853–866. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hadad U, Thauland TJ, Martinez OM, Butte MJ, Porgador A and Krams SM: NKp46 clusters at the immune synapse and regulates NK cell polarization. Front Immunol. 6:4952015. View Article : Google Scholar : PubMed/NCBI
22	North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, Anderson R and Lowdell MW: Tumor-primed human natural killer cells lyse NK-resistant tumor targets: Evidence of a two-stage process in resting NK cell activation. J Immunol. 178:85–94. 2007. View Article : Google Scholar : PubMed/NCBI
23	Iizuka K, Chaplin DD, Wang Y, Wu Q, Pegg LE, Yokoyama WM and Fu YX: Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci USA. 96:6336–6340. 1999. View Article : Google Scholar : PubMed/NCBI
24	Fogel LA, Sun MM, Geurs TL, Carayannopoulos LN and French AR: Markers of nonselective and specific NK cell activation. J Immunol. 190:6269–6276. 2013. View Article : Google Scholar : PubMed/NCBI
25	Burt BM, Plitas G, Stableford JA, Nguyen HM, Bamboat ZM, Pillarisetty VG and DeMatteo RP: CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis. J Leukoc Biol. 84:1039–1046. 2008. View Article : Google Scholar : PubMed/NCBI
26	Blasius AL, Barchet W, Cella M and Colonna M: Development and function of murine B220⁺CD11c⁺NK1.1⁺ cells identify them as a subset of NK cells. J Exp Med. 204:2561–2568. 2007. View Article : Google Scholar : PubMed/NCBI
27	Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M and Zimmer J: Human CD56^bright NK cells: An update. J Immunol. 196:2923–2931. 2016. View Article : Google Scholar : PubMed/NCBI
28	Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P and Liu Y: Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood. 108:246–252. 2006. View Article : Google Scholar : PubMed/NCBI
29	Clinthorne JF, Beli E, Duriancik DM and Gardner EM: NK cell maturation and function in C57BL/6 mice are altered by caloric restriction. J Immunol. 190:712–722. 2013. View Article : Google Scholar : PubMed/NCBI
30	Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, Degli-Esposti MA, Smyth MJ, Tarlinton DM and Nutt SL: NK cell maturation and peripheral homeostasis is associated with KLRG1 upregulation. J Immunol. 178:4764–4770. 2007. View Article : Google Scholar : PubMed/NCBI
31	Ballas ZK, Buchta CM, Rosean TR, Heusel JW and Shey MR: Role of NK cell subsets in organ-specific murine melanoma metastasis. PLoS One. 8:e655992013. View Article : Google Scholar : PubMed/NCBI
32	Alter G, Malenfant JM and Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 294:15–22. 2004. View Article : Google Scholar : PubMed/NCBI
33	Neagu M, Constantin C and Longo C: Chemokines in the melanoma metastasis biomarkers portrait. J Immunoassay Immunochem. 36:559–566. 2015. View Article : Google Scholar : PubMed/NCBI
34	Neagu M, Constantin C and Tanase C: Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev Mol Diagn. 10:897–919. 2010. View Article : Google Scholar : PubMed/NCBI
35	Neagu M, Caruntu C, Constantin C, Boda D, Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin carcinogenesis: Updates in experimental models (Review). Oncol Rep. 35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
36	Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 11:3354–3360. 2016. View Article : Google Scholar : PubMed/NCBI
37	Isvoranu G, Marinescu B, Surcel M, Ursaciuc C and Manda G: Immunotherapy in cancer - in vivo study of the anti-tumor activity of the IL-15/IL-15R alfa combination in an experimental model of melanoma. Farmacia. 63:631–636. 2015.
38	Isvoranu G: The memory activation of NK cells: New methods in cancer immunotherapy. Immunotherapy: Myths, Reality, Ideas, Future. Metodiev K: IntechOpen, London: pp. 201–219. 2017
39	Zaharescu I, Moldovan AD and Tanase C: Natural killer (NK) cells and their involvement in different types of cancer. Current status of clinical research. J Mind Med Sci. 4:31–37. 2017. View Article : Google Scholar
40	Tanase CP, Albulescu R and Neagu M: Application of 3D hydrogel microarrays in molecular diagnostics: Advantages and limitations. Expert Rev Mol Diagn. 11:461–464. 2011. View Article : Google Scholar : PubMed/NCBI